NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) Trial

NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) Trial
 

The Trial

View Infographic

 

NCI-MATCH precision medicine clinical trial will explore treating patients based on the molecular profiles of their tumors.

NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) is a clinical trial that analyzes patients’ tumors to determine whether they contain genetic abnormalities for which a targeted drug exists (that is, “actionable mutations”) and assigns treatment based on the abnormality. NCI-MATCH seeks to determine whether treating cancers according to their molecular abnormalities will show evidence of effectiveness.
NCI-MATCH can add new treatments or drop treatments over time. Each treatment will be used in a unique arm, or substudy, of the trial.
The trial opened for enrollment in August 2015 with 10 arms. Each arm will enroll adults 18 years of age and older with advanced solid tumors and lymphomas that are no longer responding (or never responded) to standard therapy and have begun to grow......

 Enrolling in NCI-MATCH

To learn more about this trial, patients should start by speaking with their doctors or healthcare team. More details about the trial are available in the protocol summary. As the year progresses, the list of clinical sites will continue to grow as new sites are added.

Patients, families, and clinicians can also call  NCI’s Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for assistance in English and Spanish or contact NCI's LiveHelp service.

Clinicians and organizations that are interested in participating in this trial should contact NCI's Cancer Trials Support UnitExit Disclaimer.